Sigma Planning Corp Makes New $907,000 Investment in Moderna, Inc. $MRNA

Key Points

• Sigma Planning Corp initiated a new position in Moderna (MRNA) in Q4, buying 30,761 shares valued at approximately $907,000.
• Moderna reported Q results with ($3.40) EPS (missed consensus of ($3.02)) but $389 million in revenue (beat estimates), a 260.2% year‑over‑year increase.
• Insiders have been selling (President Stephen Hoge sold 160,009 shares for about $7.8M) while analysts' consensus is a "Reduce" rating with an average price target of $35.73.

Sigma Planning Corp purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 30,761 shares of the company's stock, valued at approximately $907,000.

A number of other institutional investors also recently bought and sold shares of MRNA. Invesco Ltd. lifted its holdings in Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company's stock worth $212,223,000 after buying an additional 1,115,131 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Moderna during the 2nd quarter worth about $23,192,000. Bank of America Corp DE lifted its holdings in Moderna by 84.3% during the 2nd quarter. Bank of America Corp DE now owns 1,779,309 shares of the company's stock worth $49,091,000 after buying an additional 813,974 shares during the last quarter. Theleme Partners LLP lifted its holdings in Moderna by 8.6% during the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company's stock worth $217,100,000 after buying an additional 626,420 shares during the last quarter. Finally, Telemark Asset Management LLC purchased a new stake in Moderna during the 3rd quarter worth about $12,915,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of recent analyst reports. Morgan Stanley set a $33.00 price target on Moderna in a report on Friday. Wall Street Zen upgraded Moderna from a "sell" rating to a "hold" rating in a research report on Saturday, January 17th. Citigroup reiterated a "neutral" rating on shares of Moderna in a research report on Monday, February 16th. The Goldman Sachs Group lifted their target price on Moderna from $43.00 to $49.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Evercore set a $35.00 target price on Moderna in a research report on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $35.73.

Insider Activity

In related news, Director Abbas Hussain sold 5,682 shares of the business's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director owned 12,066 shares in the company, valued at $562,637.58. The trade was a 32.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 160,009 shares of the business's stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56. Following the completion of the transaction, the president owned 1,457,427 shares in the company, valued at $71,180,734.68. This trade represents a 9.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 10.80% of the company's stock.

Moderna Stock Up 4.3%

MRNA opened at $47.30 on Tuesday. The business's 50-day simple moving average is $51.84 and its 200-day simple moving average is $39.47. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a one year low of $22.28 and a one year high of $59.55. The stock has a market capitalization of $18.68 billion, a P/E ratio of -5.80 and a beta of 1.05.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts' consensus estimates of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm's revenue for the quarter was up 260.2% on a year-over-year basis. During the same quarter last year, the firm posted ($2.52) EPS. Analysts anticipate that Moderna, Inc. will post -8 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.